The silencing of MCL-1 was shown to sensitize or prime cancer cells to cytotoxic chemotherapy and BCL-2 family antagonists in ALL, rhabdomyosarcoma, and neuroblastoma [123,124,125,126]. Here, BCL2 is linked to neuroblastoma.